Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
Sarepta axes late-phase DMD drug over safety signal, FDA talks
The safety signal deprived Sarepta of a near-term shot at accelerated approval—and took down the biotech’s entire PPMO franchise.
Nick Paul Taylor
Nov 7, 2024 7:45am
Wave surfs DMD success to regulators' doors, sending stock up
Sep 24, 2024 9:51am
Capricor sells Europe rights to late-stage DMD therapy for $35M
Sep 18, 2024 5:55am
Dyne shakes up C-suite after hazy DMD data drop
Sep 3, 2024 11:49am
Analysts dig into Avidity's DMD win, revealing nuances in data
Aug 12, 2024 9:24am
Pfizer takes $230M hit after axing failed DMD gene therapy
Jul 30, 2024 8:15am
